Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796415 | 1.00 | GRM5 (1.00) | GRM5KCNH2P2RX7 | |
| SCHEMBL24969391 | 0.92 | GRM5 (1.00) | GRM5KCNH2P2RX7 | |
| SCHEMBL24969384 | 0.90 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL30794682 | 0.85 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL505129 | 0.81 | GRM5 (0.68) | GRM5KCNH2 | |
| SCHEMBL24969791 | 0.79 | GRM5 (1.00) | GRM5KCNH2 | |
| SCHEMBL505190 | 0.78 | GRM5 (0.64) | GRM5KCNH2 | |
| SCHEMBL504777 | 0.75 | GRM5 (0.69) | GRM5KCNH2 | |
| SCHEMBL505046 | 0.73 | GRM5 (0.74) | GRM5KCNH2 | |
| SCHEMBL504821 | 0.71 | GRM5 (0.64) | GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028659-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028659-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | FABP3, TNNC1, TNNI3 | GRM5 4/4885KCNH2 1009/4885P2RX7 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.